Candel Therapeutics

Candel develops cancer immunotherapies designed to improve the lives of cancer patients and their families. The company's immunotherapies focus on preventing the recurrence and progression of cancer with low toxicity level which is well suited for the treatment of less aggressive or slower growing cancers such as newly diagnosed prostate cancer, enabling physicians to ensure improved outcomes for their patients and help them recover faster.

Candel Therapeutics headquartered in United States, North America, operates in the Biotechnology, Health Care, Medical, Therapeutics, Genetics, Health Diagnostics sector. The company focuses on Biotechnology and has secured $27.7B in funding across 168 round(s). With a team of 11-50 employees, Candel Therapeutics is actively contributing to advancements in Biotechnology. Their latest funding round, Grant - Candel Therapeutics, raised $500.0K. Discover more about their projects, partnerships, and impact on our platform.